Balyasny Asset Management
TRVI icon

Balyasny Asset Management’s Trevi Therapeutics TRVI Stock Holding History

Balyasny Asset Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.8M Buy
845,087
+371,238
+78% +$5.4M 0.02% 835
2026
Q1 		$5.65M Buy
473,849
+299,208
+171% +$3.35M 0.01% 1320
2025
Q4 		$2.19M Sell
174,641
-451,821
-72% -$5.22M ﹤0.01% 1806
2025
Q3 		$5.73M Sell
626,462
-1,727,940
-73% -$13M 0.01% 1308
2025
Q2 		$12.9M Buy
2,354,402
+595,783
+34% +$3.71M 0.02% 850
2025
Q1 		$11.1M Buy
+1,758,619
New +$8.39M 0.02% 861

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Balyasny Asset Management's TRVI Position: Q2 2026 in Review

Balyasny Asset Management increased its Trevi Therapeutics (TRVI) stake by 78% in Q2 2026, buying an estimated $5.4M and bringing the position to 845,087 shares worth $15.8M. The position accounts for 0.02% of the portfolio, ranked #835.

Balyasny Asset Management first reported a position in TRVI in Q1 2025 and has held it in 6 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Balyasny Asset Management held 845,087 shares of Trevi Therapeutics worth $15.8M as of Q2 2026.
  • Balyasny Asset Management bought 371,238 Trevi Therapeutics shares in Q2 2026, an estimated $5.4M.
  • Trevi Therapeutics made up 0.02% of Balyasny Asset Management's portfolio in Q2 2026, its #835 holding.
  • Balyasny Asset Management first reported a position in Trevi Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.